#### Inpatient Burden of Respiratory Syncytial Virus Infection and Influenza in Children Younger 1 than 5 years in Japan, 2011-2022: A database study 2

3 4

Takeshi Arashiro<sup>1,2,3</sup>, Rolf Kramer<sup>4</sup>, Jing Jin<sup>5</sup>, Munehide Kano<sup>1</sup>, Fangyuan Wang<sup>6</sup>, Isao Miyairi<sup>7</sup>

- 5
- <sup>1</sup>Sanofi Vaccines Medical, Tokyo, Japan 6
- 7 <sup>2</sup>Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine,
- London, United Kingdom 8
- <sup>3</sup>School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki, Japan 9
- <sup>4</sup>Sanofi Vaccines Medical, Lyon, France 10
- <sup>5</sup>Sanofi Vaccines Medical, Beijing, China 11
- <sup>6</sup>Real World Evidence, Syneos Health, Beijing, China 12
- <sup>7</sup>Department of Pediatrics, School of Medicine, Hamamatsu University, Hamamatsu, Japan 13
- 14

# 15

- Corresponding Author: Takeshi Arashiro (Takeshi.Arashiro@sanofi.com) 16
- Running Title: RSV and influenza in young children in Japan 18

19

17

20

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

### 21 Abstract (250/250 words)

### 22 Background

23 Respiratory syncytial virus (RSV) and influenza virus are major viral etiologies of pediatric lower

respiratory tract infection, but comparative data on inpatient burden are lacking.

25 Methods

Using a large-scale health claims database in Japan, we identified patients under 5 years of age with a confirmed RSV or influenza diagnosis as an outpatient or inpatient between 2011-2022. Hospitalization rate, inpatient characteristics, various in-hospital outcomes/complications, and healthcare resource utilization were described.

30 **Results** 

A total of 176,911 RSV-confirmed outpatients, 153,383 influenza-confirmed outpatients, 90,413 RSV-

32 confirmed hospitalizations, and 11,186 influenza-confirmed hospitalizations were identified. Among

outpatients, 24.7% of RSV infection and 2.8% of influenza cases required hospitalization within one

week. There was no comorbidities/prematurity for 95.0% of RSV hospitalizations and 96.5% of

35 influenza hospitalizations. Proportions of in-hospital outcomes/complications were (RSV infection vs

influenza): oxygen use 47.6% vs 14.8%, mechanical ventilation 2.1% vs 0.7%, pneumonia 33.6% vs

12.8%, otitis media 7.7% vs 2.3%, febrile seizure 1.5% vs 34.4%, encephalitis/encephalopathy 0.1% vs

0.5%, myocarditis <0.1% vs 0.6%, antibiotics prescription 48.0% vs 24.4%. The mean inpatient stay

was 6.1 vs 4.3 days at direct medical costs of 435,744 vs 315,809 JPY/patient. These trends held true in

<sup>40</sup> age-stratified data. In-hospital death occurred in 31 RSV infection and 6 influenza cases.

# 41 Conclusions

42 Although both infections resulted in substantial burden, RSV infection led to more frequent

43 hospitalizations, worse in-hospital outcomes, longer inpatient stays, higher medical costs, and more

44 frequent antibiotics prescription compared to influenza. Most RSV hospitalizations occurred among

<sup>45</sup> healthy term children, emphasizing the need for prevention measures in all children.

**Keywords:** pediatrics; respiratory syncytial virus infections; influenza; hospitalization; Japan

# 49 Main Text

# 50 Introduction

Lower respiratory tract infections (LRTIs) are major public health threats among young children. 51 Among pediatric LRTIs, respiratory syncytial virus (RSV) and influenza virus are major viral etiologies 52 with high burden globally.<sup>1,2</sup> In Japan, the National Epidemiological Surveillance of Infectious Diseases 53 (NESID) is conducted by the National Institute of Infectious Diseases (NIID) and Ministry of Health, 54 Labour and Welfare (MHLW).<sup>3</sup> For RSV infection and influenza, under the NESID, sentinel 55 surveillance provides information on trends and levels of epidemics to inform policy, risk 56 communication, and (for RSV infection) timing to initiate prophylaxis to individuals with underlying 57 health conditions or prematurity.<sup>4,5</sup> However, the NESID data only provides age-stratified aggregate 58 data regardless of clinical severity. Therefore, detailed and comprehensive burden data on severe cases 59 require special studies and such data are scarce in Japan. Most previous reports on severe cases of LRTI 60 are based on small studies that describe single-center/single-prefecture experience or studies with only a 61 brief description of in-hospital outcomess.<sup>6-8</sup> Furthermore, although RSV and influenza share several 62 clinical features in young children, comparative data on inpatient characteristics, inpatient outcomes, 63 complications, and healthcare resource utilization (HCRU) is lacking globally. Finally, epidemiology of 64 RSV infection and influenza has been disrupted globally due to the coronavirus disease (COVID-19) 65 pandemic and further data especially around epidemic shift in age group are warranted.<sup>9,10</sup> Therefore, 66 we used one of the largest health claims databases in Japan to comprehensively describe RSV infection 67 and influenza in children with the aim to elucidate hospitalization rate among infected individuals, 68 inpatient characteristics, inpatient outcomes, and HCRU. 69

# 71 Methods

# 72 Database and study population

This retrospective cohort study was conducted using data from the Medical Data Vision (MDV) 73 database, one of the largest electronic health records databases in Japan covering approximately 450 74 hospitals (25% of acute care hospitals in Japan). The present study population was comprised of 75 patients under five years of age with a confirmed index diagnosis of RSV or influenza either outpatient 76 or inpatient based on the International Classification of Diseases 10th Revision (ICD-10) diagnostic 77 codes (Supplementary Table 1) within an identification period of April 1, 2011 to July 31, 2022. 78 Diagnoses which occurred within 6-months of the index diagnosis of the same infection (wash-out 79 period) were excluded to avoid duplicating the same episode. Patients with a record of another infection 80 with different pathogen within 30 days after the index date (e.g., suspected co-infection) were also 81 excluded. 82

83

# 84 Baseline characteristics

<sup>85</sup> Data on age at diagnosis, sex, diagnosis date, and hospital size were collected. A 12-month look-<sup>86</sup> back period from the index date was used to define the baseline period during which presence of <sup>87</sup> comorbidities/prematurity and palivizumab use were ascertained. Comorbidities included in this study <sup>88</sup> were those eligible to receive palivizumab in Japan (ICD-10 codes in **Supplementary Table 1**).<sup>11-14</sup>

89

#### 90 Definitions of hospitalized patients, clinical outcomes, healthcare resource utilization, and

*hospitalization rates* 

To describe inpatient characteristics including baseline characteristics, inpatient outcomes, and HCRU, we included all patients who had a confirmed diagnosis in the inpatient setting regardless of where or whether an outpatient RSV diagnosis was made (to ensure inclusion of patients who were diagnosed with RSV infection at different healthcare facilities such as clinics and patients who were

never diagnosed before being hospitalized and diagnosed after hospitalization). To be identified as a 96 relevant hospitalization, the infection had to have been coded as any of the following: (1) the disease 97 that required the most medical resources, (2) primary disease for admission, or (3) disease that triggered 98 the hospitalization. Patients who were admitted to the hospital were followed to examine in-hospital 99 clinical outcomes and HCRU beginning from the index date and ending at the time of in-hospital death, 100 discharge, the last record available for the patient, or the end of the study period (August 31, 2022), 101 whichever occurred first. Variables for examination included intravenous (IV) fluid use, oxygen use, 102 high flow-nasal canula oxygen therapy use, use of mechanical ventilation, intensive care unit (ICU) 103 admissions, in-hospital death, antibiotics use, in-hospital complications (pneumonia, otitis media, 104 febrile seizure, encephalitis or encephalopathy, and myocarditis). Finally, length of inpatient stay and 105 direct medical costs during hospitalization for each patient were calculated by including all procedures, 106 clinical exams, imaging, and medications (in Japanese yen). 107

For the purpose of calculating hospitalization rate among outpatients, we divided the number of 108 patients with a confirmed index outpatient diagnosis by the number of patients who had a confirmed 109 inpatient diagnosis in the same hospital. This was done to ensure that patients included in the numerator 110 (hospitalized cases) were also in the denominator (outpatient cases). The basis of this algorithm was the 111 assumption that almost all patients diagnosed in an outpatient clinic of a hospital will be admitted to the 112 same hospital if the patient's condition deteriorates to the point of requiring inpatient care, as per 113 clinical practice in Japan. The date of first admission was used to estimate the percentage of eligible 114 patients hospitalized within 0-6 days, 0-13 days, and 0-29 days of the index date. Percent 115 hospitalizations within these time intervals were also calculated specifically for patients who required 116 oxygen or intravenous (IV) fluids to restrict to those requiring medical attention. 117

118

119 Analyses

120	We took a descriptive approach to understand baseline characteristics, hospitalizations rates, in-
121	hospital clinical outcomes, and HCRU. We concluded that it would not be appropriate to estimate the
122	relative measures of association (e.g., odds ratios) to compare such parameters between RSV
123	infection and influenza, as various confounders (e.g., testing intensity) may exist. Instead, whenever
124	possible, we presented data for the overall population, as well as data stratified by age since age is an
125	important cofounder that influences various outcomes. Age categories used were less than 6 months,
126	6 months-1 year, 1-2 years, and 2-4 years of age (summary data were also presented by month for
127	less than 1 year). Continuous variables were summarized with means/standard deviations (SD) and
128	median/interquartile range (IQR). Categorical variables were summarized using counts and
129	percentages.
130	Epidemic curves for outpatients and inpatients for RSV infection and influenza were created to
131	describe temporal trends. Finally, to understand the influence of the COVID-19 pandemic on
132	epidemiology, analyses were also performed and stratified by time period, including 2017-2019 (pre-
133	COVID-19), 2020-2022 (during-COVID-19), and the 2021 season (as this season showed a unique
134	RSV epidemic curve <sup>3</sup> ). All analyses were performed using SAS software (version 9.4).

#### 136 **Results**

During the study period between April 2011 and July 2022, 176,911 RSV-confirmed cases and 137 153,383 influenza-confirmed cases were identified in the outpatient setting (Figure 1; Supplementary 138 Tables 2-3). Furthermore, 90,413 RSV-confirmed hospitalizations and 11,186 influenza-confirmed 139 hospitalizations were identified (overall Table 1; healthy children Supplementary Table 4). For both 140 RSV infection and influenza, there were more males than females. Among hospitalized RSV cases, 141 39.0% were less than 6 months, 20.8% were 6 months-1 year, 26.4% were 1-2 years, and 13.7% were 2-142 4 years. Among hospitalized influenza cases, 19.1% were less than 6 months, 10.6% were 6 months-1 143 year, 25.4% were 1-2 years, and 44.8% were 2-4 years. Among inpatients, 85,896/90,413 (95.0%) of 144 RSV cases and 10,789/11,186 (96.5%) of influenza cases occurred in patients with no record of relevant 145 comorbidities or prematurity. Supplementary Table 5 shows the data among infants by month of age. 146 Regarding the epidemic curves for influenza, a clear seasonal pattern in wintertime was observed 147 with no epidemic occurring in late 2020-2022 (Figure 2; Supplementary Table 6). In contrast, RSV 148 infection also had epidemic peaks, but with considerable year-to-year variability. Specifically, before 149 and during 2016, the peaks were from fall to winter. In 2017-2019, peaks began and ended earlier 150 spanning summer to fall. There was no epidemic in 2020, but the largest wave was observed in 2021 151 peaking in early summer. These findings were in line with the corresponding NESID data. Also, 152 importantly, trends and levels of epidemics were similar between inpatients and outpatients for both 153 RSV infection and influenza, respectively. 154

Hospitalization rate among confirmed outpatient RSV diagnosis was 43,637/176,911 (24.7%) within 6 days of diagnosis (**Table 2**). This rate was similar when restricting to hospitalization requiring oxygen/IV usage (42,277/176,911; 23.9%). When stratified by age group, the highest percentage of hospitalization was observed among the 1-2 years age category (11,995/42,485; 28.2%), although this could be due to less outpatient testing (**Supplementary Methods**). Also, hospitalization rate within 6 days of diagnosis among healthy children was higher (41,666/141,843; 29.4%) than the non-restricted

population and the highest percentage was observed for the less than 6 months age category within 29 161 days of diagnosis (15,717/45,318; 34.7%). In contrast, hospitalization rate among confirmed outpatient 162 influenza diagnosis was much lower at 4,247/153,383 (2.8%) within 6 days of diagnosis. When 163 stratified by age group, the highest percentage of hospitalization was observed among those less than 6 164 months age (736/8,741; 8.4%). 165

Various in-hospital outcomes/HCRU-related factors were described (Table 3). IV fluid was used in 166 86,258/90,413 (95.4%) of RSV cases and 10,622/11,186 (95.0%) of influenza cases. Oxygen was 167 required in 43,056/90,413 (47.6%) of RSV cases and 1,656/11,186 (14.8%) of influenza cases. 168 Mechanical ventilation was required in 1,928/90,413 (2.1%) of RSV cases and 74/11,186 (0.7%) of 169 influenza cases. In-hospital death occurred in 31/90,413 (<0.1%) of RSV cases and 6/11,186 (0.1%) of 170 influenza cases. Antibiotics were prescribed in 43,418/90,413 (48.0%) of RSV cases and 2,728/11,186 171 (24.4%) of influenza cases. The mean inpatient stays were 6.1 days and 4.3 days with direct medical 172 costs of 435,744JPY/patient and 315,809JPY/patient for RSV infection and influenza, respectively. 173 Regarding in-hospital complications, pneumonia occurred in 30,376/90,413 (33.6%) of RSV cases and 174 1,428/11,186 (12.8%) of influenza cases. Otitis media occurred in 6,915/90,413 (7.7%) of RSV cases 175 and 255/11,186 (2.3%) of influenza cases. Febrile seizure occurred in 1,366/90,413 (1.5%) of RSV 176 cases and 3,843/11,186 (34.4%) of influenza cases. Encephalitis or encephalopathy occurred in 177 49/90,413 (0.1%) of RSV cases and 54/11,186 (0.5%) of influenza cases. Myocarditis occurred in 178 4/90,413 (<0.1%) of RSV cases and 68/11,186 (0.6%) of influenza cases. 179 Finally, we stratified the number of hospitalizations by COVID-19 era (Supplementary Tables 7-180 8). There was a comparatively lower proportion of RSV hospitalizations in age <6 months and age 6-11 181 months during COVID-19 era (36.4%, 15.1%) and 2021 season (35.9%, 14.3%) compared to pre-182 COVID-19 era (39.3%, 21.9%). Conversely, there was a comparatively higher proportion of RSV 183 hospitalizations in age 2 years to 4 years during COVID-19 era (21.3%) and 2021 season (22.0%)

184

- compared to pre-COVID-19 era (12.0%). There were very few influenza hospitalizations during
- 186 COVID-19 era.

# 188 Discussion

We conducted a study using large electronic health records database covering approximately 25% of acute care hospitals in Japan to elucidate the comprehensive inpatient burden of RSV infection and influenza in young children. We found that a large number of RSV and influenza cases were diagnosed in both outpatient and inpatient settings with substantial in-hospital outcomes/complications and HCRU during the 11-year study period.

Similar to what has been observed in previous reports<sup>1</sup>, over half of RSV hospitalizations occurred 194 in infants less than 1 year of age. Approximately 95% of these RSV hospitalizations occurred in patients 195 with no record of comorbidities or prematurity. We also observed hospitalization rates among children 196 diagnosed with RSV infection to be 20-30%, meaning that one in four medically-attended RSV 197 infections resulted in hospitalization. When restricting to patients without comorbidities/prematurity, 198 the rates were even higher (up to 35%), which is likely to be due to unavailability of prevention 199 measures in this population (unlike palivizumab for children with comorbidities/prematurity). These 200 were in stark contrast to low hospitalization rates for influenza where only 2-3% in children 6 months of 201 age or older and 8-9% among infants less 6 months of age. 202

We further examined in-hospital outcomes and HCRU related to each infection. Important in-203 hospital outcomes including oxygen use, ICU admission, and mechanical ventilation were more 204 prevalent with RSV infections compared to influenza across all age groups. Still, ICU admission and 205 mechanical ventilation among the RSV inpatient population were much lower compared to the data 206 from the U.S., which could be due to a lower threshold of hospitalization in Japan and scarcity of 207 pediatric ICUs in Japan (i.e., some specialized care including mechanical ventilation is routinely done in 208 general wards).<sup>15</sup> Although the numbers and proportions were small, a few in-hospital deaths occurred 209 for both infections. Antibiotic use was more prevalent for RSV infection than for influenza. This could 210 be due to more severe in-hospital outcomes for RSV infection and improved antimicrobial stewardship 211 is warranted. Regarding in-hospital complications, pneumonia and otitis media were more common in 212

RSV infection than in influenza. In contrast, febrile seizures, encephalitis/encephalopathy, and 213 myocarditis were more common in influenza than in RSV infection. Notably, approximately one-third 214 of influenza hospitalization were associated with febrile seizure. Longer inpatient stays (6.1 vs 4.3 days) 215 with higher direct medical costs (435,744 vs 315,809 JPY/patient) were observed with RSV infection 216 compared with influenza. Finally, analyses by COVID-19 era revealed a slight shift in age of RSV 217 hospitalizations to older age groups in 2021-2022, which is in line with lack of epidemic in 2020. This 218 shift may recover to pre-COVID-19 trends after a few years of epidemics together with disrupted 219 seasonal pattern as observed in the U.S.<sup>10</sup> 220 Given the substantial burden of RSV infection with considerable in-hospital 221 outcomes/complications and HCRU, the currently available RSV prophylaxis, palivizumab, which only 222 covers children with specific comorbidities or prematurity, is not enough to protect the majority of 223 children from hospitalization when infected, similar to influenza where routine vaccination is available. 224 Novel RSV prevention measures to protect all children are needed. Recently, another monoclonal 225 antibody with extended half-life, nirsevimab, has been approved for use as a preventative treatment for 226 all infants entering their first RSV season in the U.S. and several other countries.<sup>16</sup> Maternal 227 immunization is also approved for use, although only available in a seasonal manner with a narrow 228 window period for immunization (pregnant individuals at 32-36 weeks gestational age) in the U.S.<sup>17</sup> 229 There are other potential preventive measures for toddlers under development.<sup>18</sup> The current study 230 highlights that the burden of severe RSV infection in children in Japan and other countries are similarly. 231 Therefore, improved awareness of disease burden as well as wide use of these preventive measures are 232 highly anticipated upon approval. 233

234

# 235 Limitations

There are several limitations to this study. First, the current database is based on participating hospitals only and there is no linkage of data across hospitals. Second, although both RSV and influenza

238	testing is covered by NHI (Supplementary Methods), careful interpretation is necessary as testing
239	intensity may differ between RSV infection and influenza as well as by age group (especially infants vs
240	young children >1 years). Third, the database did not have information on influenza vaccination/anti-
241	viral use, which may have influenced study outcomes. Nevertheless, the availability of
242	prevention/treatment for influenza and unavailability to prevention/treatment for RSV infection is
243	reflection of real-world disease burden from RSV disease, which may improve with novel prevention
244	measures mentioned above. Finally, similar to other database studies, medical coding may not always
245	reflect true diagnosis or procedures.
246	
247	Conclusions
248	A large number of RSV and influenza cases were diagnosed in both Japanese outpatient and
249	inpatient settings during the study period. There were also substantial in-hospital
250	outcomes/complications and HCRU, many of which were more frequently observed with RSV infection

compared to influenza. Furthermore, longer inpatient stays with more expensive direct medical costs

<sup>252</sup> were seen with RSV infection compared to influenza. Approximately one in four RSV infection resulted

in hospitalization with most hospitalization occurring among healthy term children, emphasizing the

need for RSV prevention measures in all children.

# **Funding Information**

- <sup>257</sup> This work was supported by Sanofi and AstraZeneca.
- 258

# 259 **Potential Conflicts of Interest**

<sup>260</sup> Takeshi Arashiro is a Sanofi employee and a cooperative researcher at the National Institute of

<sup>261</sup> Infectious Diseases, Japan. Rolf Kramer, Jing Jin, and Munehide Kano are Sanofi employees. Fangyuan

<sup>262</sup> Wang is a Syneos Health employee. Isao Miyairi received honoraria from Sanofi for lectures and

advisory committees.

264

# 265 Ethics Statement

The study was conducted under the ethical principles consistent with the Japanese Ethical Guidelines for Medical and Biological Research Involving Human Subjects and the Declaration of Helsinki. The requirement for informed consent was waived as all personal and identifying data were anonymized in the administrative health claims dataset.

270

# 271 Author Contributions

All authors contributed to the conception and/or design of the study; TA and FW were involved in data analyses; TA, RK, and IM were involved in interpretation of the data; TA drafted the first version of the manuscript. All authors critically reviewed the manuscript for intellectual content and gave final approval of the version to be published.

276


### 277 Acknowledgements

We thank employees of Syneos Health for technical assistance in study design and data analysis. We also thank Ko Nakajo for technical assistance in study conception and design.

# **Figure Legends**


# Figure 1. Description of the flow for assembling the outpatient population used to calculate

### 283 hospital admission rates



# Figure 2. Epidemic curve for RSV and influenza identified in outpatient and inpatient settings.

- (A) Outpatient RSV infection, (B) inpatient RSV infection, (C) outpatient influenza, (D) inpatient
- 287 influenza



288

#### References 290

- 1. Li Y, Wang X, Blau DM et al. Global, regional, and national disease burden estimates of acute 291 lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 292 2019: a systematic analysis. Lancet. 2022;399(10340):2047-64. 293
- Wang X, Li Y, O'Brien KL et al. Global burden of respiratory infections associated with 2. 294 seasonal influenza in children under 5 years in 2018: a systematic review and modelling study. 295 Lancet Glob Health. 2020;8(4):e497-e510. 296
- National Institute of Infectious Diseases. Weekly Infectious Disease Report. 3. 297
- https://www.niid.go.jp/niid/ja/idwr.html. Accessed December 23, 2023. (In Japanese) 298 National Institute of Infectious Diseases. Influenza Epidemiological Information. 4. 299
- https://www.niid.go.jp/niid/ja/diseases/a/flu.html. Accessed December 23, 2023. (In Japanese) 300 National Institute of Infectious Diseases. RS Virus Infections 2018-2021. Infectious Agents 5. 301
- Surveillance Report. 2022;43(4):79-81. (In Japanese) 302
- Nagasawa K, Ishiwada N. Disease burden of respiratory syncytial virus infection in the pediatric 6. 303 population in Japan. J Infect Chemother. 2022;28(2):146-57. 304
- 7. Kobayashi Y, Togo K, Agosti Y, McLaughlin JM. Epidemiology of respiratory syncytial virus 305 in Japan: A nationwide claims database analysis. Pediatr Int. 2022;64(1):e14957. 306
- Mashiba S, Takahashi T, Hayashi N et al. Features of patients with influenza virus infection 8. 307 examined in the emergency department of a university hospital in north-western Japan. J Int 308 Med Res. 2004;32(3):331-6. 309
- 9. Bardsley M, Morbey RA, Hughes HE et al. Epidemiology of respiratory syncytial virus in 310 children younger than 5 years in England during the COVID-19 pandemic, measured by 311 laboratory, clinical, and syndromic surveillance: a retrospective observational study. Lancet 312 Infect Dis. 2023;23(1):56-66. 313
- 10. Hamid SW, A, Parikh R, Jones J et al. Seasonality of Respiratory Syncytial Virus - United 314 States, 2017–2023. Morbidity and Mortality Weekly Report (MMWR). 2023;72(14):355-61. 315
- Gantenberg JR, van Aalst R, Zimmerman N et al. Medically Attended Illness due to Respiratory 11. 316 Syncytial Virus Infection Among Infants Born in the United States Between 2016 and 2020. J 317 Infect Dis. 2022;226(Suppl 2):S164-s74. 318
- Bennett MV, McLaurin K, Ambrose C, Lee HC. Population-based trends and underlying risk 12. 319 factors for infant respiratory syncytial virus and bronchiolitis hospitalizations. PLoS One. 320 2018:13(10):e0205399. 321
- Mori M, Yoshizaki K, Watabe S et al. Safety, efficacy and pharmacokinetics of palivizumab in 13. 322 off-label neonates, infants, and young children at risk for serious respiratory syncytial virus 323 infection: a multicenter phase II clinical trial. Lancet Reg Health West Pac. 2023;39100847. 324
- 14. AstraZeneca. Notification of Partial Change Approval Application for the Humanized 325 Monoclonal Antibody Against RS Virus, "Synagis". https://www.astrazeneca.co.jp/media/press-326 releases1/2023/2023070301.html. Accessed December 23, 2023. (In Japanese) 327
- 15. Arriola CS, Kim L, Langley G et al. Estimated Burden of Community-Onset Respiratory 328 Syncytial Virus-Associated Hospitalizations Among Children Aged <2 Years in the United 329 States, 2014-15. J Pediatric Infect Dis Soc. 2020;9(5):587-95. 330
- Sanofi. Press Release: FDA approves Beyfortus<sup>™</sup> (nirsevimab-alip) to protect infants against 16 331 RSV disease. https://www.sanofi.com/en/media-room/press-releases/2023/2023-07-17-17-00-332 00-2705911. Accessed December 23, 2023. 333
- U.S. Food & Drug Administration. ABRYSVO. https://www.fda.gov/vaccines-blood-17. 334 biologics/abrysvo. Accessed December 23, 2023. 335
- 18. PATH. RSV Vaccine and mAb Snapshot. https://www.path.org/resources/rsv-vaccine-and-mab-336 snapshot/. Accessed December 23, 2023. 337
- 338

			RSV					Influenza		
	Total	Age <6 months	Age 6-11 months	Age 1<2 years	Age 2<5 years	Total	Age <6 months	Age 6-11 months	Age 1<2 years	Age 2<5 years
Total number of patients, n (relative % by	90,413	35,273	18,827	23,898	12,415	11,186	2,141	1,188	2,845	5,012
age group)	(100)	(39.0)	(20.8)	(26.4)	(13.7)	(100)	(19.1)	(10.6)	(25.4)	(44.8)
Sex, n (%)										
Female	40,958	15,564	8,030	11,133	6,231	4,890	986	517	,	2,105
1 childre	(45.3)	(44.1)	(42.7)	(46.6)	(50.2)	(43.7)	(46.1)	(43.5)		(42.0)
Male	49,455	19,709	10,797	12,765	6,184	6,296	1,155	671		2,907
	(54.7)	(55.9)	(57.4)	(53.4)	(49.8)	(56.3)	(54.0)	(56.5)	(54.9)	(58.0)
Age, months						(24.0				(40.7)
Mean (SD)	(11.8, 11.1)	(2.5, 1.4)	(8.4, 1.7)	(16.7, 3.4)	(33.9, 8.7)	(24.0,	(2.6, 1.3)	(8.6, 1.7)	(17.4, 3.3)	(40.7,
						17.4)			$\begin{array}{c} 2,845\\(25.4)\\ 1,282\\(45.1)\\1,563\\(54.9)\\ (17.4,3.3)\\17.0\\(14.0-20.0)\\ 79\\(2.8)\\129\\(4.5)\\223\\(7.9)\\275\\(9.7)\\403\\(14.2)\\348\\(12.3)\\396\\(13.9)\\490\\(17.3)\\491\\(17.3)\\0\\(0.0)\\3\\(0.1)\\ \end{array}$	10.6)
Median (IQR)	9.0	2.0	8.0	16.0	32.0	21.0	2.0	9.0		40.0
Wedian (IQK)	(3.0-17.0)	(1.0-4.0)	(7.0-10.0)	(14.0-19.0)	(27.0-40.0)	(9.0-38.0)	(2.0-3.0)	(7.0-10.0)	(14.0-20.0)	(31.0-50.0)
Season by year, n (%)										
2011 (May 2011 to April 2012)	2,000	724	451	547	278	360	70	38		173
2011 (May 2011 to April 2012)	(2.2)	(2.1)	(2.4)	(2.3)	(2.2)	(3.2)	(3.3)	(3.2)		(3.5)
2012 (May 2012 to April 2013)	3,609	1,367	845	940	457	517	99	44	$\begin{array}{c} (25.4) \\ 1,282 \\ (45.1) \\ 1,563 \\ (54.9) \\ \hline \\ (17.4, 3.3) \\ 17.0 \\ (14.0-20.0) \\ \hline \\ 79 \\ (2.8) \\ 129 \\ (4.5) \\ 223 \\ (7.9) \\ 275 \\ (9.7) \\ 403 \\ (14.2) \\ 348 \\ (12.3) \\ 396 \\ (13.9) \\ 490 \\ (17.3) \\ 491 \\ (17.3) \\ 0 \\ (0.0) \\ 3 \end{array}$	245
2012 (May 2012 to April 2013)	(4.0)	(3.9)	(4.5)	(3.9)	(3.7)	(4.6)	(4.6)	(3.7)		(4.9)
2013 (May 2013 to April 2014)	5,259	2,252	1,191	1,227	589	933	147	99		464
	(5.8)	(6.4)	(6.3)	(5.1)	(4.8)	(8.4)	(6.9)	(8.4)		(9.3)
2014 (May 2014 to April 2015)	8,057	3,223	1,793	2,038	1,003	1,142	262	117		488
	(8.9)	(9.1)	(9.5)	(8.5)	(8.1)	(10.2)	(12.3)	(9.9)		(9.8)
2015 (May 2015 to April 2016)	9,532 (10.6)	3,834 (10.9)	2,057 (10.9)	2,464 (10.3)	1,177	1,575 (14.1)	231 (10.8)	202 (17.1)		739 (14.8)
	(10.6) 8,926	3,626	2,057	2,302	(9.5) 941	(14.1) 1,378	302	(17.1) 128		(14.8) 600
2016 (May 2016 to April 2017)	(9.9)	(10.3)	(10.9)	(9.6)	(7.6)	(12.4)	(14.1)	(10.8)		(12.0)
	13,434	5,148	2,987	3,588	1,711	1,677	303	174		804
2017 (May 2017 to April 2018)	(14.9)	(14.6)	(15.9)	(15.0)	(13.8)	(15.0)	(14.2)	(14.7)		(16.1)
	12,356	5,105	2,754	3,148	1,349	1,895	423	186		796
2018 (May 2018 to April 2019)	(13.7)	(14.5)	(14.6)	(13.2)	(10.9)	(17.0)	(19.8)	(15.7)		(16.0)
2010 (Marc 2010 to Ameril 2020)	11,576	4,380	2,382	3,313	1,501	1,660	296	194		679
2019 (May 2019 to April 2020)	(12.8)	(12.4)	(12.7)	(13.9)	(12.1)	(14.9)	(13.9)	(16.4)	(17.3)	(13.6)
2020 (May to December)	802	304	166	238	94	3	1	2	0	Ò
2020 (May to December)	(0.9)	(0.9)	(0.9)	(1.0)	(0.8)	(0.0)	(0.1)	(0.2)	(0.0)	(0.0)
2021 (January to December)	12,396	4,456	1,771	3,438	2,731	6	1	1	3	1
2021 (January to December)	(13.7)	(12.6)	(9.4)	(14.4)	(22.0)	(0.1)	(0.1)	(0.1)	Age 1<2 years 2,845 (25.4) 1,282 (45.1) 1,563 (54.9) (17.4, 3.3) 17.0 (14.0-20.0) 79 (2.8) 129 (4.5) 223 (7.9) 275 (9.7) 403 (14.2) 348 (12.3) 396 (13.9) 490 (17.3) 491 (17.3) 0 (0.0) 3	(0.0)
2022 (January to July)	2,410	832	362	638	578	4	1	0	e	0
· · · · · ·	(2.7)	(2.4)	(1.9)	(2.7)	(4.7)	(0.0)	(0.1)	(0.0)	(0.1)	(0.0)
Comorbidity during baseline period, n (%)	205	100	0.1	- 4	22	20	2		2	
Down syndrome	387	123	91	74	99	20	3	4	2	11

**Table 1** Baseline characteristics for all children hospitalized with RSV infection and influenza overall and by age categories

	(0.4)	(0.4)	(0.5)	(0.3)	(0.8)	(0.2)	(0.1)	(0.3)	(0.1)	(0.2)
Congenital heart disease	1,817	902	501	264	150	119	36	33	29	21
	(2.0)	(2.6)	(2.7)	(1.1)	(1.2)	(1.1)	(1.7)	(2.8)	(1.0)	(0.4)
Bronchopulmonary dysplasia	110 (0.1)	40 (0.1)	42 (0.2)	18 (0.1)	10 (0.1)	5 (0.0)	(0.1)	2 (0.2)	(0.0)	(0.0)
	1,979	1,288	(0.2) 546	(0.1) 122	(0.1) 23	(0.0) 79	35	(0.2)	(0.0)	(0.0)
Prematurity	(2.2)	(3.7)	(2.9)	(0.5)	(0.2)	(0.7)	(1.6)	(3.0)	(0.2)	(0.0)
Immunodoficionary	169	68	45	35	21	29	4	6	5	14
Immunodeficiency	(0.2)	(0.2)	(0.2)	(0.2)	(0.2)	(0.3)	(0.2)	(0.5)	(0.2)	(0.3)
Pulmonary hypoplasia	19	10	4	2	3	2	1	1	0	0
i minerany nypepinera	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.1)	(0.1)	(0.0)	(0.0)
Airway stenosis	36 (0.0)	9 (0.0)	9 (0.1)	13	5	2 (0.0)	$\begin{pmatrix} 0 \\ (0, 0) \end{pmatrix}$	0 (0.0)	2 (0.1)	0 (0.0)
	(0.0)	(0.0)	(0.1)	(0.1)	(0.0)	(0.0)	(0.0) 0	(0.0)	(0.1)	(0.0)
Esophageal atresia	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)
	378	82	100	115	81	93	3	9	32	49
Congenital metabolic disorder	(0.4)	(0.2)	(0.5)	(0.5)	(0.7)	(0.8)	(0.1)	(0.8)	(1.1)	(1.0)
Neuromuscular disorder	358	68	77	106	107	100	1	13	30	56
	(0.4)	(0.2)	(0.4)	(0.4)	(0.9)	(0.9)	(0.1)	(1.1)	(1.1)	(1.1)
Cystic fibrosis	$\begin{pmatrix} 0 \\ (0 \\ 0 \end{pmatrix}$	$\begin{pmatrix} 0 \\ (0, 0) \end{pmatrix}$	$\begin{pmatrix} 0 \\ (0, 0) \end{pmatrix}$	$\begin{pmatrix} 0 \\ (0 \\ 0 \end{pmatrix}$	0	$\begin{pmatrix} 0 \\ (0 \\ 0 \end{pmatrix}$	$\begin{pmatrix} 0 \\ (0, 0) \end{pmatrix}$	$\begin{pmatrix} 0 \\ (0 \\ 0 \end{pmatrix}$	$\begin{pmatrix} 0 \\ (0, 0) \end{pmatrix}$	0
	(0.0) 85,896	(0.0) 32,977	(0.0) 17,671	(0.0) 23,251	(0.0) 11,997	(0.0) 10,789	(0.0) 2,064	(0.0) 1,100	(0.0) 2,750	(0.0) 4,875
No record of these comorbidities	(95.0)	(93.5)	(93.9)	(97.3)	(96.6)	(96.5)	(96.4)	(92.6)	(96.7)	(97.3)
Palivizumab use, n (%)	()))	(55.5)	(55.5)	() (13)	()0.0)	()0.0)	(50.1)	()2:0)	(50.7)	(37.3)
Yes	1,559	706	453	354	46	82	16	28	33	5
Tes	(1.7)	(2.0)	(2.4)	(1.5)	(0.4)	(0.7)	(0.8)	(2.4)	(1.2)	(0.1)
No record of use	88,854	34,567	18,374	23,544	12,369	11,104	2,125	1,160	2,812	5,007
Size of healthcare facilities, n (%)	(98.3)	(98.0)	(97.6)	(98.5)	(99.6)	(99.3)	(99.3)	(97.6)	(98.8)	(99.9)
	5,252	1,781	1,209	1,454	808	551	68	55	156	272
Less than 200 beds	(5.8)	(5.1)	(6.4)	(6.1)	(6.5)	(4.9)	(3.2)	(4.6)	(5.5)	(5.4)
200 / 100 1 1	50,876	19,056	11,029	13,859	6,932	6,090	1,138	640	1,578	2,734
200 to 499 beds	(56.3)	(54.0)	(58.6)	(58.0)	(55.8)	(54.4)	(53.2)	(53.9)	(55.5)	(54.6)
500 or more beds	34,285	14,436	6,589	8,585	4,675	4,545	935	493	1,111	2,006
	(37.9)	(40.9)	(35.0)	(35.9)	(37.7)	(40.6)	(43.7)	(41.5)	(39.1)	(40.0)

Rounding may create totals slightly over or below 100% in some cases.

**Table 2.** Percentage of first hospitalizations after confirmed diagnosis of RSV or influenza at the outpatient setting in Japan among the overall population and after restricting to healthy children

			RSV					Influe		
	Total	Age <6 months	Age 6-11 months	Age 1<2 years	Age 2<5 years	Total	Age <6 months	Age 6-11 months	Age 1<2 years	Age 2<5 years
All Children										
Total confirmed diagnoses at outpatient	176,911	70,021	39,311	42,485	25,094	153,383	8,741	16,295	39,218	89,129
setting, n, (relative % by age group)	(100)	(39.6)	(22.2)	(24.0)	(14.2)	(100)	(5.7)	(10.6)	(25.6)	(58.1)
Overall hospitalizations after diagnosis										
(n, % of outpatient diagnoses)										
	43,637	16,560	8,903	11,995	6,179	4,247	736	441	1,126	1,944
Admissions within 0-6 days	(24.7)	(23.7)	(22.7)	(28.2)	(24.6)	(2.8)	(8.4)	(2.7)	(2.9)	(2.2)
	43,805	16,645	8,949	12,024	6,187	4,270	739	444	1,135	1,952
Admissions within 0-13 days	(24.8)	(23.8)	(22.8)	(28.3)	(24.7)	(2.8)	(8.5)	(2.7)	(2.9)	(2.2)
Admissions within 0-29 days	44,281	16,869	9,090	12,116	6,206	4,327	740	448	1,156	1,983
Aumssions within 0-29 days	(25.0)	(24.1)	(23.1)	(28.5)	(24.7)	4,527 (2.8)	(8.5)	(2.8)	(3.0)	(2.2)
Hospitalizations with oxygen/IV usage (n, % of outpatient diagnoses)	(23.0)	(24.1)	(23.1)	(20.3)	(27.7)	(2.0)	(0.5)	(2.0)	(3.0)	(2.2)
	42,277	15,713	8,715	11,841	6,008	4,089	695	426	1,092	1,876
Admissions within 0-6 days	(23.9)	(22.4)	(22.2)	(27.9)	(23.9)	(2.7)	(8.0)	(2.6)	(2.8)	(2.1)
	42,421	15,787	8,755	11,865	6,014	4,112	698	429	1,101	1,884
Admissions within 0-13 days	(24.0)	(22.6)	(22.3)	(27.9)	(24.0)	(2.7)	(8.0)	(2.6)	(2.8)	(2.1)
	42,881	15,998	8,894	11,956	6,033	4,167	699	433	1,122	1,913
	(24.2)	(22.9)	(22.6)	(28.1)	(24.0)	(2.7)	(8.0)	(2.7)	(2.9)	(2.2)
Admissions within 0-29 days	(=)	()	()	(2011)	()	()	(0.0)	()	()	()
Healthy Children										
•	141,843	45,318	33,225	39,545	23,755	149,529	8,197	15,277	38,019	88,036
Overall hospitalizations after diagnosis n, (relative % by age group)	(100)	(31.9)	(23.4)	(27.9)	(16.7)	(100)	(5.5)	(10.2)	(25.4)	(58.9)
Overall hospitalizations after diagnosis, n, (% of outpatient diagnoses)										
Admissions within 0-6 days	41,666	15,717	8,443	11,573	5,933	4,020	694	386	1,066	1,874
········· · ····················	(29.4)	(34.7)	(25.4)	(29.3)	(25.0)	(2.7)	(8.5)	(2.5)	(2.8)	(2.1)

	41,814	15,794	8,479	11,600	5,941	4,042	697	389	1,075	1,881
	(29.5)	(34.9)	(25.5)	(29.3)	(25.0)	(2.7)	(8.5)	(2.5)	(2.8)	(2.1)
Admissions within 0-29 days	42,228	15,970	8,610	11,688	5,960	4,095	698	392	1,094	1,911
- J	(29.8)	(35.2)	(25.9)	(29.6)	(25.1)	(2.7)	(8.5)	(2.6)	(2.9)	(2.2)
Hospitalizations with oxygen/IV usage % of outpatient diagnoses)	、 <i>,</i>		~ /	、 <i>,</i>	```				、 <i>/</i>	
Admissions within 0-6 days										
	40,384	14,919	8,276	11,425	5,764	3,874	657	375	1,033	1,809
	(28.5)	(32.9)	(24.9)	(28.9)	(24.3)	(2.6)	(8.0)	(2.5)	(2.7)	(2.1)
Admissions within 0-13 days										
	40,515	14,988	8,308	11,449	5,770	3,896	660	378	1,042	1,816
	(28.6)	(33.1)	(25.0)	(29.0)	(24.3)	(2.6)	(8.1)	(2.5)	(2.7)	(2.1)
Admissions within 0-29 days	40,916	15,154	8,437	11,536	5,789	3,947	661	381	1,061	1,844
-	(28.8)	(33.4)	(25.4)	(29.2)	(24.4)	(2.6)	(8.1)	(2.5)	(2.8)	(2.1)

\*Healthy children were defined as those with children without a record of comorbidity of interest and no palivizumab use.

			RSV				Influenza						
	Total	Age <6 months	Age 6-11 months	Age 1<2 years	Age 2<5 years	Total	Age <6 months	Age 6-11 months	Age 1<2 years	Age 2< years			
Total number of patients, n (relative % by	90,413	35,273	18,827	23,898	12,415	11,186	2,141	1,188	2,845	5,012			
age group)	90,413 (100)	(39.0)	(20.8)	(26.4)	(13.7)	(100)	2,141 (19.1)	(10.6)	(25.4)	(44.8)			
Intravenous fluids use													
No	4,155	2,432	656	548	519	564	124	58	122	260			
	(4.6)	(6.9)	(3.5)	(2.3)	(4.2)	(5.0)	(5.8)	(4.9)	(4.3)	(5.2)			
Yes	86,258	32,841	18,171	23,350	11,896	10,622	2,017	1,130	2,723	4,752			
	(95.4)	(93.1)	(96.5)	(97.7)	(95.8)	(95.0)	(94.2)	(95.1)	(95.7)	(94.8)			
Oxygen use		~ /	( )	( )	( )		( )	( )					
No	47,357	19,575	9,106	12,105	6,571	9,530	2,014	1,016	2,292	4,208			
	(52.4)	(55.5)	(48.4)	(50.7)	(52.9)	(85.2)	(94.1)	(85.5)	(80.6)	(84.0)			
Yes	43,056	15,698	9,721	11,793	5,844	1,656	127	172	553	804			
	(47.6)	(44.5)	(51.6)	(49.4)	(47.1)	(14.8)	(5.9)	(14.5)	(19.4)	(16.0)			
High flow nasal canula oxygen therapy use													
No	88,117	33,791	18,426	23,614	12,286	11,162	2,137	1,185	2,841	4,999			
	(97.5)	(95.8)	(97.9)	(98.8)	(99.0)	(99.8)	(99.8)	(99.8)	(99.9)	(99.7)			
Yes	2,296	1,482	401	284	129	24	4	3	4	13			
	(2.5)	(4.2)	(2.1)	(1.2)	(1.0)	(0.2)	(0.2)	(0.3)	(0.1)	(0.3)			
Use of mechanical ventilation													
No	88,485	34,118	18,510	23,593	12,264	11,112	2,133	1,183	2,826	4,970			
	(97.9)	(96.7)	(98.3)	(98.7)	(98.8)	(99.3)	(99.6)	(99.6)	(99.3)	(99.2)			
Yes	1,928	1,155	317	305	151	74	8	5	19	42			
	(2.1)	(3.3)	(1.7)	(1.3)	(1.2)	(0.7)	(0.4)	(0.4)	(0.7)	(0.8)			
Intensive care unit (ICU) admissions													
No	89,813	34,842	18,743	23,846	12,382	11,147	2,138	1,186	2,831	4,992			
	(99.3)	(98.8)	(99.6)	(99.8)	(99.7)	(99.7)	(99.9)	(99.8)	(99.5)	(99.6)			
Yes	600	431	84	52	33	39	3	2	14	20			
	(0.7)	(1.2)	(0.5)	(0.2)	(0.3)	(0.4)	(0.1)	(0.2)	(0.5)	(0.4)			
In-hospital death													
No	90,382	35,262	18,818	23,892	12,410	11,180	2,140	1,188	2,844	5,008			
	(100)	(100)	(100)	(100)	(100)	(100)	(100)	(100)	(100)	(99.9)			
Yes	31	11	9	6	5	6	1	0	1	4			
	(0.0)	(0.0)	(0.1)	(0.0)	(0.0)	(0.1)	(0.1)	(0.0)	(0.0)	(0.1)			
Antibiotics use													
No	46,995	23,461	8,854	9,337	5,343	8,458	1,792	866	2,067	3,733			
	(52.0)	(66.5)	(47.0)	(39.1)	(43.0)	(75.6)	(83.7)	(72.9)	(72.7)	(74.5)			
Yes	43,418	11,812	9,973	14,561	7,072	2,728	349	322	778	1,279			
	(48.0)	(33.5)	(53.0)	(60.9)	(57.0)	(24.4)	(16.3)	(27.1)	(27.4)	(25.5)			
In-hospital complications	a a a = -	< <b>-</b>											
Pneumonia	30,376	6,590	6,484	11,353	5,949	1,428	115	158	413	742			

Table 3. Clinical outcomes and healthcare resource utilization and cost for children hospitalized with RSV infection and influenza

(33.6)	(18.7)	(34.4)	(47.5)	(47.9)	(12.8)	(5.4)	(13.3)	(14.5)	(14.8)
	· ·	· ·		-			-		91
		· /			. ,				(1.8) 2,115
									(42.2)
49		2		11	. ,	4	5	24	21
(0.1)	(0.1)	(0.0)	(0.1)	(0.1)	(0.5)	(0.2)	(0.4)	(0.8)	(0.4)
4	1	1	1	1	68	1	5	15	47
(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.6)	(0.1)	(0.4)	(0.5)	(0.9)
6.1 (3.3)	6.3 (3.7)	6.2 (2.9)	5.9 (3.4)	5.7 (2.5)	4.3 (2.6)	4.1 (1.8)	4.5 (2.8)	4.4 (2.5)	4.3 (2.8)
6.0 (4.0-7.0)	6.0 (4.0-7.0)	6.0 (4.0-7.0)	5.0 (4.0-7.0)	5.0 (4.0-7.0)	4.0 (3.0-5.0)	4.0 (3.0-4.0)	4.0 (3.0-5.0)	4.0 (3.0-5.0)	4.0 (3.0-5.0)
435,743.8 (271,703.1)	453,731.5 (314,856.1)	434,766.4 (248,195.8)	420,035.9 (243,875.7)	416,362.1 (215,192.6)	315,809.4 (209,438.7)	292,933.0 (151,420.1)	327,031.6 (248,576.5)	330,289.5 (234,427.2)	314,702.2 (204,736.6
391,648.5 (286,581.3-	402,215.5 (291,487.7-	391,262.3 (286,157.9-	3847,67.1 (283,405.0-	380722.7 (280912.3-	2821,85.4 (207,122.7-	272,527.0 (200,339.0-	287,527.1 (217,363.1-	295,797.2 (219,178.9-	279,503.3 (202,282.5
	6,915 (7.7) 1,366 (1.5) 49 (0.1) 4 (0.0) 6.1 (3.3) 6.0 (4.0-7.0) 435,743.8 (271,703.1) 391,648.5	$\begin{array}{rrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrr$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$

All costs are noted in Japanese Yen, Rounding may create totals slightly over or below 100% in some cases; Abbreviations: IQR, interquartile range; SD, standard deviation